MET and breast carcinoma: SOCS7 loss has resulted in the amplification of HGF/C-MET growth and migrational signalling in the two studied breast cancer cell lines, but pharmacological blockade of PLCγ-1 enzymatic activity has mitigated this amplified signalling.